Short answer
Axsome Therapeutics, Inc. (AXSM) filed its Q2 2026 10-Q quarterly report on Aug 10, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $218M (up 45.5% year over year) with net income of −$51M.
Q2 2026 key financials · XBRL
- Revenue
- $218M
- +45.5% YoY · +14.2% QoQ
- Net income
- −$51M
- −7.0% YoY · +20.5% QoQ
- Operating margin
- -22.7%
- EPS (diluted)
- −$0.99
- −3.1% YoY · +21.4% QoQ
Source: XBRL data from the Axsome Therapeutics, Inc. (AXSM) Q2 2026 10-Q on SEC EDGAR. USD.
Axsome Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly heightened tariff risk: April 2026 proclamation imposes up to 100% tariffs on imported patented pharmaceuticals and ingredients
- Debt risk: Blackstone revolver commitments increased $20.0 million to $90.0 million, with minimum liquidity covenant of $30.0 million
- Regulatory risk: BIOSECURE Act restricts U.S. government procurement involving designated biotechnology companies of concern
- Operational risk: Tariff-driven supplier changes could disrupt manufacturing and derail commercialization plans
- Financial risk: Net loss reached $115.9 million for six months ended June 30, 2026, versus $107.4 million in 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Axsome Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.